Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Perrigo is a Dublin-domiciled manufacturer and distributor of over-the-counter healthcare products and generic prescription pharmaceuticals, operating primarily across North America and Europe. The company focuses on store-brand consumer health products (pain relievers, cough/cold, skincare) sold through major retailers like Walmart and CVS, competing on price and retailer relationships rather than brand equity. Recent performance reflects margin pressure from input cost inflation, competitive intensity in generic pharmaceuticals, and portfolio rationalization efforts following divestitures.
Perrigo generates revenue by manufacturing private-label OTC products at scale for major retailers, capturing margin through manufacturing efficiency and retailer volume commitments rather than consumer brand loyalty. The business model relies on long-term supply agreements with retailers who seek lower-cost alternatives to national brands, with Perrigo earning 20-40% gross margins depending on product complexity and competitive intensity. Pricing power is limited as retailers can switch suppliers, making operational efficiency and product development speed critical to maintaining shelf space and volume.
Gross margin trajectory driven by raw material costs (APIs, resins, packaging) and pricing negotiations with major retail customers
Market share gains or losses in key OTC categories, particularly analgesics and cough/cold where competition from branded generics and other private-label suppliers is intense
New product launches and speed-to-market for store-brand equivalents following branded OTC switches or new category entries
European Consumer Self-Care performance, which carries higher margins and branded exposure but faces currency headwinds and regional economic sensitivity
Free cash flow generation and debt reduction progress given elevated leverage (0.86x D/E) and need to fund working capital and capex
Retailer consolidation and increasing private-label manufacturing in-house by major chains (Amazon Basics, Walmart's own facilities) threatens long-term volume and pricing power
Regulatory complexity in OTC-to-Rx switches and international markets (EU MDR, FDA monograph reforms) increases compliance costs and slows new product introductions
Commoditization of generic OTC categories with limited differentiation opportunities, creating persistent margin pressure as competition intensifies from Indian and Chinese manufacturers
Competition from vertically integrated retailers developing their own manufacturing capabilities and from lower-cost offshore suppliers in India and China
Branded pharmaceutical companies defending OTC franchises through aggressive pricing, consumer marketing, and product innovation (e.g., extended-release formulations)
Loss of key retailer contracts or shelf space to competitors offering better pricing or service levels, with limited ability to replace volume quickly
Elevated debt levels (0.86x D/E) relative to current profitability (2.6% operating margin) limit financial flexibility for acquisitions, capex, or weathering operational challenges
Negative net margin (-3.9%) and ROE (-1.2%) indicate profitability challenges that could pressure covenant compliance if performance deteriorates further
Working capital intensity in OTC distribution with inventory risk from product expiration, retailer returns, and demand volatility in seasonal categories like cough/cold
low-to-moderate - OTC healthcare products exhibit defensive characteristics as consumers continue purchasing pain relievers, cough/cold remedies, and basic skincare regardless of economic conditions. However, discretionary categories like premium skincare and vitamins show modest cyclicality. Retailer inventory management becomes more conservative during economic uncertainty, impacting order patterns and working capital. Generic Rx volumes are largely non-cyclical but face reimbursement pressure.
Rising interest rates increase borrowing costs on Perrigo's debt load (0.86x D/E ratio), pressuring free cash flow available for debt reduction or reinvestment. Higher rates also compress valuation multiples for low-growth, cash-generative businesses like Perrigo. However, the company's floating-rate exposure is limited, and the primary impact is through refinancing risk and opportunity cost of capital allocation decisions.
Moderate - Perrigo's retailer customers (Walmart, CVS, Walgreens, Kroger) have strong credit profiles, minimizing receivables risk. However, tightening credit conditions could pressure retailer inventory management and promotional spending, indirectly affecting order volumes. The company's own credit profile (investment-grade equivalent) provides access to capital markets, but covenant compliance and leverage ratios become more scrutinized during credit stress.
value - The stock trades at distressed multiples (0.5x P/S, 0.5x P/B, 8.8x EV/EBITDA) reflecting operational challenges and turnaround uncertainty, attracting deep-value investors betting on margin recovery and free cash flow normalization. The 12.2% FCF yield appeals to investors focused on cash generation despite negative net income. Recent 41% one-year decline has created potential entry point for contrarian investors expecting stabilization in Consumer Self-Care Americas and European market recovery.
high - The stock exhibits elevated volatility driven by quarterly earnings surprises, retailer contract wins/losses, and margin volatility from input costs and competitive pricing. Recent 38% six-month decline followed by 14% three-month recovery demonstrates significant price swings. Beta likely exceeds 1.2x given operational leverage, small-cap characteristics ($2B market cap), and limited institutional ownership providing less price stability.
